Abstract
Background:Everolimus is a mammalian target of rapamycin inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between pre-treatment neutrophil-to-lymphocyte ratio (NLR) and the outcome of patients treated with everolimus for mRCC.Methods:Ninety-seven patients with mRCC were treated with everolimus till April 2013 in our institutions. Patients were stratified in two groups with NLR >3 (Group A) vs
| Original language | English |
|---|---|
| Pages (from-to) | 1755-1759 |
| Number of pages | 5 |
| Journal | British Journal of Cancer |
| Volume | 109 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Oct 1 2013 |
Fingerprint
Keywords
- everolimus
- mTOR inhibitors
- neutrophil-tolymphocyte ratio
- renal cell carcinoma
- targeted therapy
- tyrosine kinase inhibitor
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. / Santoni, M.; De Giorgi, U.; Iacovelli, R.; Conti, A.; Burattini, L.; Rossi, L.; Luca Burgio, S.; Berardi, R.; Muzzonigro, G.; Cortesi, E.; Amadori, D.; Cascinu, S.
In: British Journal of Cancer, Vol. 109, No. 7, 01.10.2013, p. 1755-1759.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma
AU - Santoni, M.
AU - De Giorgi, U.
AU - Iacovelli, R.
AU - Conti, A.
AU - Burattini, L.
AU - Rossi, L.
AU - Luca Burgio, S.
AU - Berardi, R.
AU - Muzzonigro, G.
AU - Cortesi, E.
AU - Amadori, D.
AU - Cascinu, S.
PY - 2013/10/1
Y1 - 2013/10/1
N2 - Background:Everolimus is a mammalian target of rapamycin inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between pre-treatment neutrophil-to-lymphocyte ratio (NLR) and the outcome of patients treated with everolimus for mRCC.Methods:Ninety-seven patients with mRCC were treated with everolimus till April 2013 in our institutions. Patients were stratified in two groups with NLR >3 (Group A) vs
AB - Background:Everolimus is a mammalian target of rapamycin inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between pre-treatment neutrophil-to-lymphocyte ratio (NLR) and the outcome of patients treated with everolimus for mRCC.Methods:Ninety-seven patients with mRCC were treated with everolimus till April 2013 in our institutions. Patients were stratified in two groups with NLR >3 (Group A) vs
KW - everolimus
KW - mTOR inhibitors
KW - neutrophil-tolymphocyte ratio
KW - renal cell carcinoma
KW - targeted therapy
KW - tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=84885182189&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885182189&partnerID=8YFLogxK
U2 - 10.1038/bjc.2013.522
DO - 10.1038/bjc.2013.522
M3 - Article
C2 - 24008663
AN - SCOPUS:84885182189
VL - 109
SP - 1755
EP - 1759
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 7
ER -